Arine, a leader in AI-based medication intelligence, announced a Series C funding round. Town Hall Ventures led the round with participation from Kaiser Permanente Ventures and other existing investors.
This $30 million round brings Arine’s total funding to $66 million, solidifying its position at the forefront of healthcare innovation. The company is now empowered to accelerate its mission of redefining medication management across the healthcare continuum, a time when the industry faces unprecedented financial and regulatory pressures.
Arine’s AI platform focuses on the essential areas of medication optimization, delivering scalable, personalized, and cost-effective medication therapy that is essential to success in value-based care. Created for leading health plan and risk-bearing providers, Arine’s platform utilizes large and diverse datasets to identify the right individuals, recommend the most effective interventions, and continuously measure impact to ensure meaningful outcomes.
How the funding will be used: With the new funding round, Arine will focus on several key areas to meet evolving industry needs. And Arine plans to expand its capabilities in specialty pharmacy management. And at the same time, the company is accelerating AI innovation to automate high-volume, low-complexity tasks, enabling providers to focus more on direct patient care.
Arine will also continue to integrate comprehensive data to further personalize medication therapy. Together, these advancements expand Arine’s impact and set a new standard for how technology can drive scalable, meaningful change in healthcare.
KEY QUOTES:
“This is a defining moment for healthcare and for Arine. Mounting cost pressures and sweeping policy changes are forcing the industry to rethink how care is delivered. Amid these challenges, medications have emerged as one of the most powerful—and underleveraged—tools to improve outcomes and control costs. With this new capital, we’re expanding our ability to deliver meaningful impact for each patient, when the system needs it most.”
Yoona Kim, PharmD, PhD, CEO and co-founder of Arine
“The rising cost of medications and the consequences of suboptimal medication use presents significant opportunities for innovation, particularly using AI. What sets Arine apart is not just its transformative technology, but its ability to consistently deliver measurable value for clients across populations, especially in underserved communities. The company’s phenomenal leadership team combines deep clinical and AI expertise with a bold vision for the future. Their platform is not just solving today’s problems—it’s anticipating tomorrow’s challenges. We’re proud to support Arine as they drive the next wave of healthcare innovation.”
Andy Slavitt, General Partner at Town Hall Ventures
“We’ve been partnering with Arine since 2020, and year after year, the value has been clear. Arine continues to expand the capabilities of their platform in ways that drive even greater impact—advancing evidence-based quality, improving patient-centered outcomes, and delivering meaningful cost savings. It’s that ongoing evolution that makes them such a valuable long-term partner.”
Caroline Carney, MD, MSc, FAPA, FAPM, CPHQ, President and Chief Medical Officer at Magellan Health
